A new analysis looked at a gene called SLC25A28 in glioma, a type of brain tumor. The researchers combined data from several large glioma datasets and also did lab experiments with glioma cells. They found that people with lower levels of SLC25A28 tended to have shorter overall survival. When they pooled data from nine groups, the risk of death was about 1.91 times higher for those with lower expression. The link held in both IDH-mutant and IDH-wild-type subgroups, though results within glioblastoma were mixed. Lab tests showed glioma cells had lower SLC25A28 than normal brain cells. The study has important limits. The survival link is an association, not proof of cause. There was high variability between the pooled groups, and some subgroup findings were inconsistent. The work is at an early stage, and SLC25A28 is not a validated clinical test. Readers should see this as a research lead, not a tool for making treatment decisions.
Lower SLC25A28 expression linked to shorter survival in glioma, pooled HR 1.91Low SLC25A28 Linked to Shorter Survival in Glioma
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This meta-analysis combined multi-cohort bioinformatic analyses of glioma datasets (CGGA, TCGA, and nine GlioVis cohorts) with in vitro experiments in U87 and U251 glioma cell lines. The authors examined whether SLC25A28 (mitoferrin-2) expression is associated with clinicopathological features and overall survival.
Lower SLC25A28 expression was associated with unfavorable clinicopathological features and shorter overall survival, with a pooled hazard ratio of 1.91 (95% CI 1.46-2.50) across the nine GlioVis cohorts. Heterogeneity was high (I2 = 84.9%). Exploratory subgroup analyses suggested survival associations in both IDH-mutant and IDH-wild-type tumors, though findings within glioblastoma varied.
The review also reported positive associations between SLC25A28 expression and oxidative phosphorylation that persisted after grade and IDH adjustment in pooled cohorts, but within glioblastoma this was supported in CGGA and not TCGA. Ferroptosis-related transcriptional associations were detected, with scoring-method and cohort dependence in regulator signatures. Immune-cell differences survived FDR correction for 10 of 22 populations in CGGA and 16 of 22 in TCGA, and three checkpoint genes showed positive correlations in both cohorts. In vitro, qRT-PCR and Western blotting confirmed lower SLC25A28 expression in U87 and U251 cells than in normal human astrocytes.
The authors note several limitations: variability within glioblastoma, cohort-dependent findings, and the need for subtype-specific clinical validation and functional investigations. No safety data were reported. SLC25A28 is described as a candidate prognostic biomarker; clinical utility is not established.
How this fits prior evidence
This meta-analysis extends prior coverage of glioma biology, which has focused on malignant cell states, immunosuppressive niches, and imaging surrogates. It introduces SLC25A28 as a candidate prognostic biomarker, with a pooled hazard ratio of 1.91 (95% CI 1.46-2.50) for lower expression and shorter survival. Unlike prior preclinical work on lysine crotonylation and RPN1, this analysis is observational and multi-cohort, with high heterogeneity (I2 = 84.9%). The immune-cell correlations reported here (10 of 22 populations in CGGA, 16 of 22 in TCGA) are consistent with the interest in immune microenvironment features in glioblastoma, but do not establish causality.
Common questions
What is SLC25A28 and how does it relate to glioma?
SLC25A28 is a gene that helps transport iron into mitochondria. In this study, lower expression of SLC25A28 was linked to shorter survival in glioma. The research combined data from several cohorts and lab experiments, but it does not prove that SLC25A28 causes glioma to grow or spread.
Is SLC25A28 a reliable test for glioma prognosis?
Not yet. The study found a statistical link, but the evidence is early and has high variability between groups. SLC25A28 is not a validated clinical biomarker, so it should not be used to make treatment decisions. Talk to your doctor about proven tests for glioma.
What were the main limitations of this study?
The study looked at associations, not cause and effect. There was high heterogeneity (I² = 84.9%) in the pooled survival analysis, and some findings within glioblastoma differed between cohorts. The lab experiments used cell lines, not patients. More research is needed before any clinical use.
More on Glioblastoma
View Original Abstract ↓
First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer
Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival
Related in Oncology
From Other Specialties
